Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V212 in Adults With Autoimmune Disease
NCT01527383Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2012
- Primary completion
- Feb 2013
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 2, randomised, double-blind trial in herpes zoster (HZ) comparing V212 with Placebo (2 arms). Primary endpoints: Geometric Mean Fold Rise in Varicella-Zoster Antibody Responses Measured by Glycoprotein Enzyme-linked Immunosorbent Assay, Geometric Mean Fold Rise in VZV Antibody Response Measured by VZV Interferon-gamma Enzyme-linked Immunospot Assay and 1 more. Started Feb 2012; status: completed.
02
Drugs
zoster vaccine live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT01527383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01527383.